Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna
byCharles Gross
February 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0